Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
Asif S, Baxevanidi E, Hill A, Venter WDF, Fairlie L, Masenya M, Serenata C, Sokhela S, Chandiwana N. Asif S, et al. Among authors: chandiwana n. AIDS. 2021 Dec 15;35(Suppl 2):S117-S125. doi: 10.1097/QAD.0000000000003020. AIDS. 2021. PMID: 34261099
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A. Venter WDF, et al. Among authors: chandiwana n. N Engl J Med. 2019 Aug 29;381(9):803-815. doi: 10.1056/NEJMoa1902824. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31339677 Clinical Trial.
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Venter WDF, et al. Among authors: chandiwana n. Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1. Lancet HIV. 2020. PMID: 33010240 Clinical Trial.
Impact of long-acting therapies on the global HIV epidemic.
Chandiwana NC, Serenata CM, Owen A, Rannard S, Pérez Casas C, Scott C, Hill A, Clayden P, Flexner C. Chandiwana NC, et al. AIDS. 2021 Dec 15;35(Suppl 2):S137-S143. doi: 10.1097/QAD.0000000000003102. AIDS. 2021. PMID: 34848580
Weight gain stopping/switch rules for antiretroviral clinical trials.
Venter WDF, Sokhela S, Calmy A, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Sekwese K, Mashabane N, Pozniak A, Khoo S, Ali M, Delaporte E, Lalla-Edwards S, Clayden P, Marconi VC, Siedner MJ, Boffito M, Serenata C, Carman M, Collins S. Venter WDF, et al. Among authors: chandiwana n. AIDS. 2021 Dec 15;35(Suppl 2):S183-S188. doi: 10.1097/QAD.0000000000003092. AIDS. 2021. PMID: 34848585 Free PMC article.
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials.
Venter F, Sokhela S, Calmy A, Siedner MJ, Khoo S, Clayden P, Mkhondwane L, Bosch B, Chandiwana N, Hill A, Marconi VC, Boffito M, Sekwese K, Ali M, Delaporte E, Pozniak A, Mashabane N, Lalla-Edwards S, Carman M, Collins S. Venter F, et al. Among authors: chandiwana n. AIDS. 2022 Nov 1;36(13):1900-1901. doi: 10.1097/QAD.0000000000003310. AIDS. 2022. PMID: 36172876 No abstract available.
34 results